A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT04609826 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia

Interventions

DRUG: JNJ-74856665
DRUG: AZA
DRUG: VEN

Sponsor

Janssen Research & Development, LLC